Epizyme Stock News

Epizyme (EPZM) to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.

Epizyme (EPZM) to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.

Check out these penny stocks insiders are buying Losers ION Geophysical Corporation (NYSE: IO ) shares fell 53.6% to settle at $0.51 on Thursday. Epizyme, Inc. (NASDAQ: EPZM ) shares dipped 44.2% to close at $1.06 on Thursday after the company priced an underwritten public offering of 56,666,667 shares at $1.50 per share, before underwriting discounts. TG Therapeutics, Inc. (NASDAQ: TGTX ) dropped 40.5% to settle at $8.27 on Thursday. TG Therapeutics said the FDA imposed partial clinical hold on select studies of U2 and its components for CLL and NHL. Cyngn Inc. (NASDAQ: CYN ) tumbled 35.7% to close at $1.62. PetVivo Holdings, Inc. (NASDAQ: PETV ) fell 35% to close at $1.30. PetVivo recently announced distribution of its veterinary medical device, SPRYNG, by Vetcove, Inc. Advanced Human Imaging Limited (NASDAQ: AHI ) fell 33.8% to settle at $1.82. Advanced Human Imaging recently signed partnership with Activate Health OÜ. Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) dropped 33.6% to close at $0.6280.

News of a dilutive share issue left investors feeling queasy.

News of a dilutive share issue left investors feeling queasy.

News of a dilutive share issue left investors feeling queasy.

Aridis Pharmaceuticals ARDS +27%. Galapagos GLPG +16%. Immix Biopharma IMMX +15%. Epizyme (EPZM) -34%. Cue Biopharma (CUE) -16%.

The stock price of Epizyme Inc (NASDAQ: EPZM) fell by over 25% pre-market today. This is why it happened.

Epizyme <> reports its preliminary estimate for TAZVERIK product revenue to be $11.2-$11.7M for Q4 2021. TAZVERIK commercial sales is expected to be between $7.0-7.5M, representing…

Epizyme Inc (EPZM) shares closed 1.5% lower than its previous 52 week low, giving the company a market cap of $270M. The stock is currently down 76.1% year-to-date, down 77.9% over the past 12 months, and down 78.6% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 57.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -690.1% The company's stock price performance over the past 12 months lags the peer average by -739.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Invesco Ltd. increased its position in shares of Epizyme, Inc. (NASDAQ:EPZM) by 21.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 64,112 shares of the biopharmaceutical company’s stock after purchasing an additional 11,536 shares during the period. Invesco Ltd. owned […] The post Invesco Ltd. Has $533,000 Stake in Epizyme, Inc. (NASDAQ:EPZM) appeared first on ETF Daily News .

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today presented updated safety and activity data from the Phase 1b portion of its Phase 1b/3 confirmatory study evaluating the investigational use of TAZVERIK® (tazemetostat), a first-in-class, oral, selective inhibitor of EZH2, in combination with rituximab + lenalidomide (R2) in pati

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today shared preclinical data and the Phase 1/1b trial design for EZM0414, the Companys novel, first-in-class, oral SETD2 inhibitor, an investigational agent being developed for the treatment of adult patients with relapsed

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today announced that new data from across its oncology portfolio will be presented at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting, taking place from December 11 to 14, 2021 in Atlanta, Georgia. These presentations include trial design and data from combination